Pulmonary Arterial Hypertension clinical trials
The registry lists 699 studies for Pulmonary Arterial Hypertension across more than 10 countries. 140 are recruiting or about to start. 628 of them are mainly about Pulmonary Arterial Hypertension (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
ClinicalTrials.gov finds 2,098 studies for Pulmonary Arterial Hypertension. How that becomes 699 here
This page counts the studies the registry files under Pulmonary Arterial Hypertension, and those it files under no condition that list Pulmonary Arterial Hypertensionthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
- 2,098Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −18List Pulmonary Arterial Hypertension as a condition, but the registry did not file them under itMost often written as “Idiopathic Pulmonary Arterial Hypertension” (13), “Secondary Pulmonary Arterial Hypertension” (2), and “Heritable Pulmonary Arterial Hypertension” (2). The registry filed them under other conditions only, most often Familial Primary Pulmonary Hypertension (14) and Hypertension, Pulmonary (2).
- −1,381Match it another way125 name it in the title, 1 in a keyword, and 1,255 by a synonym or other text the search reads.
- 699The count on this page6 of them list Pulmonary Arterial Hypertension in their own words; the registry filed them under no condition.
Get an email when these change. Save the Pulmonary Arterial Hypertension studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Actelion (59) · United Therapeutics (44) · Bayer (19) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (13) · Novartis Pharmaceuticals (12) · Merck Sharp & Dohme LLC (12) · Bial - Portela C S.A. (12) · Assistance Publique - Hôpitaux de Paris (10)
What is being tested here
Drugs under test in Pulmonary Arterial Hypertension studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Sotatercept | 6 | 5 | 17 |
| Ambrisentan | 4 | 8 | 20 |
| Treprostinil | 3 | 14 | 44 |
| Tadalafil | 2 | 2 | 9 |
| Macitentan | 1 | 13 | 18 |
| Sildenafil | 1 | 8 | 18 |
| Selexipag | 1 | 6 | 12 |
| Iloprost | 1 | 5 | 12 |
| Ralinepag | 1 | 3 | 5 |
| Treprostinil hexadecyl ester | 1 | 2 | 4 |
Drug classes tested here Endothelin receptor antagonists 5 open · PDE5 inhibitors 3 open · Tyrosine kinase inhibitors (TKIs) 1 open · Diuretics 1 open · Bronchodilators 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension · Phase 3 · United Therapeutics
- Dec 2026Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) · Phase 3 · Gossamer Bio USA, Inc.
- Dec 2026An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) · Phase 3 · Insmed Incorporated
- Jan 2027A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option · Phase 3 · Actelion
- Nov 2026Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) · Duke University
- Nov 2026Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study · Qianfoshan Hospital
- Dec 2026PNEUMOSTEM® for Improving Respiratory Outcomes in Very Premature Infants Diagnosed With Early Pulmonary Arterial Hypertension · Samsung Medical Center
- Dec 2026Information Sources in Pulmonary Hypertension · University of Sao Paulo General Hospital
- Dec 2026A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia · Massachusetts General Hospital
- Dec 2026A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension · China National Center for Cardiovascular Diseases
Who these studies take
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger. 18 (20%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 11 (12%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 16 (18%) | 16 (18%) |
| 18 | 86 (96%) | 85 (94%) |
| 30 | 83 (92%) | 82 (91%) |
| 40 | 83 (92%) | 82 (91%) |
| 50 | 82 (91%) | 82 (91%) |
| 65 | 81 (90%) | 81 (90%) |
| 75 | 77 (86%) | 77 (86%) |
| 85 | 58 (64%) | 58 (64%) |
Across all 699 studies, recruiting or not: 33% stop at 75 or younger and 15% at 65; 19% take children; 1% are for women only and 1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Pulmonary Arterial Hypertension studies take
Of 51 phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 44 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 9 mo2–22 · 45 studies | 5 mo2–17 · 34 studies | — |
| Phase 2 | 44 mo26–65 · 51 studies | 31 mo19–48 · 28 studies | — |
| Phase 3 | 50 mo31–83 · 49 studies | 50 mo31–83 · 43 studies | — |
| Interventional, no phase | 42 mo18–71 · 65 studies | — | 44 mo18–63 · 60 studies |
| Observational | 58 mo30–93 · 85 studies | — | 60 mo31–… · 64 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting4
- Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass-SubstudyNov 10, 2026NCT07781709
- Vasopressor Agents in Pulmonary Hypertension CrisisOct 30, 2026NCT07667829
- Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)Oct 28, 2026NCT07441200
- A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)Oct 22, 2026NCT07600723
Newly registered2
- Home-based Inspiratory Muscle Training in Pulmonary HypertensionNov 4, 2026NCT07917416
- A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in KoreaOct 22, 2026NCT07890285
Studies
Recruiting first, then most recently updated. Showing 50 of 699. Browse all 699 → or search them.
- Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass-SubstudyRecruitingNCT07781709Not applicable1 country
- Clinical Trial of 2-HOBA in Pulmonary Arterial HypertensionNot yet recruitingNCT06176118Phase 2
- The Effect of Additive On-Demand Sildenafil vs. Dextrose Candy on Maximum Exercise Capacity in Pulmonary Arterial HypertensionRecruitingNCT07824674Phase 2/31 country
- Home-based Inspiratory Muscle Training in Pulmonary HypertensionNot yet recruitingNCT07917416Not applicable1 country
- A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)RecruitingNCT07600723Phase 41 country
- Spironolactone for Pulmonary Arterial HypertensionRecruitingNCT01712620Phase 21 country
- A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionRecruitingNCT05179876Phase 313 countries
- A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in KoreaNot yet recruitingNCT078902851 country
- Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)RecruitingNCT05587712Phase 212 countries
- Vasopressor Agents in Pulmonary Hypertension CrisisRecruitingNCT07667829Not applicable1 country
- A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in AdultsRecruitingNCT07143448Phase 1/23 countries
- A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) PatientsEnrolling by invitationNCT064456739 countries
- Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAHRecruitingNCT06350032Phase 35 countries
- Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I PatientsRecruitingNCT06317805Phase 412 countries
- Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)RecruitingNCT07441200Phase 21 country
- Development and Validation of a Chinese Quality of Life Scale for Pulmonary Arterial HypertensionNot yet recruitingNCT07570615
- Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)RecruitingNCT07318597Phase 210 countries
- Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT ImagingRecruitingNCT07613099Phase 31 country
- Artificial Intelligence-assisted Evaluation of Pulmonary HYpertensionRecruitingNCT055660021 country
- An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)AvailableNCT06939647
- A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)RecruitingNCT07481981Phase 38 countries
- Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)RecruitingNCT06274801Phase 330 countries
- A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)RecruitingNCT07175038Phase 29 countries
- A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionEnrolling by invitationNCT03683186Phase 333 countries
- A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)RecruitingNCT07646860Phase 21 country
- A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral SelexipagRecruitingNCT07759804Phase 41 country
- PAH-SDB: Sleep-Disordered Breathing and Outcomes in Pulmonary Arterial HypertensionRecruitingNCT078524031 country
- Hormonal, Metabolic, and Signaling Interactions in PAHRecruitingNCT018840511 country
- Tele-Pulmonary Rehabilitation For Patients With Chronic Lung DiseasesRecruitingNCT07666841Not applicable1 country
- Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO)Not yet recruitingNCT07700303Not applicable1 country
- Global Utilization And Registry Database for Improved preservAtion of doNor LUNGsEnrolling by invitationNCT049302892 countries
- A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 TabletsNot yet recruitingNCT05660863Phase 1
- Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Pulmonary Vascular Disease (PVD)RecruitingNCT07777445Not applicable1 country
- Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Chronic Lung DiseasesRecruitingNCT07777367Not applicable1 country
- DIAG723 in Adults With Hereditary Hemorrhagic TelangiectasiaRecruitingNCT07623525Phase 1/23 countries
- Assessment of Lung Function (Lufu) at Sea Level LA vs. High Altitude HA in Patients With Pulmonary Arterial Hypertension PAHNot yet recruitingNCT07804576Not applicable1 country
- Assessment of Six-minute Walking Distance 6MWD Between High Altitude HA vs. Sea Level LA in Patients With Pulmonary Arterial Hypertension PAHNot yet recruitingNCT07804472Not applicable1 country
- Assessment of Total Pulmonary Resistance sPAP/CO Between Sea Level LA vs. High Altitude HA After Re-ascent in Patients With Pulmonary Arterial Hypertension PAHNot yet recruitingNCT07804693Not applicable1 country
- Assessment of Total Pulmonary Resistance sPAP/CO Between High Altitude HA vs. Sea Level LA in Patients With Pulmonary Arterial Hypertension PAHNot yet recruitingNCT07804524Not applicable1 country
- Assessment of Heart Rate Variability HRV During Descent DE From 2850m to Sea Level and During Re-ascent A From Sea Level to 2850m in Patients With Pulmonary Arterial Hypertension PAHNot yet recruitingNCT07801859Not applicable1 country
- Sleep-Assessment in Patients Between High Altitude HA vs. Sea Level LA in Patients With Pulmonary Arterial Hypertension PAHNot yet recruitingNCT07801963Not applicable1 country
- An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)RecruitingNCT07365332Phase 314 countries
- Telerehabilitation in Pulmonary Arterial HypertensionNot yet recruitingNCT07799675Not applicable1 country
- Assessment of Six-minute Walking Distance Between Sea Level LA vs. High Altitude HA After Re-ascent in Patients With Pulmonary Arterial Hypertension PAHNot yet recruitingNCT07797166Not applicable1 country
- Exercise-based Rehabilitation in Patients With Pulmonary Arterial HypertensionRecruitingNCT06804122Not applicable1 country
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)RecruitingNCT042784042 countries
- The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) StudyRecruitingNCT05464095Not applicable1 country
- Nailfold Capillaroscopy in PHRecruitingNCT077686441 country
- Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial HypertensionRecruitingNCT06992440Phase 21 country
- CS1 Added to Standard of Care Therapy for Pulmonary Arterial HypertensionNot yet recruitingNCT07761572Phase 2